• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Value Assessment Frameworks Should Represent a Spectrum of Patient Preferences

Video

Ilene Hollin, PhD, MPH, the National Pharmaceutical Council and University of Southern California Schaeffer Center’s Postdoctoral Health Policy Fellow, discusses what needs to be included in the next generation of value assessment frameworks in order to best identify value that is representative of all patient preferences.

Ilene Hollin, PhD, MPH, the National Pharmaceutical Council and University of Southern California Schaeffer Center’s Postdoctoral Health Policy Fellow, discusses what needs to be included in the next generation of value assessment frameworks in order to best identify value that is representative of all patient preferences.

Transcript (slightly modified)

What would you like to see included in the next generation of value assessment frameworks to better identify value?

In the next generation of value assessment frameworks, we need to make sure that they are able to account for patient preference in a way that the patient and the physician can understand what is the value of a therapy given a patient’s specific set of preferences. To do this, we need to do a few things. First, we need to think about preferences much earlier in the development process. This way we can make sure that therapies are developed with patient preferences in mind, and then the clinical outcomes that are designed to measure the efficacy of those therapies are the outcomes that matter to patients.

Once we have those outcomes, patient preferences need to be incorporated into the actual value assessment and then, finally, the value assessment must offer a range of values to represent the spectrum of patient preferences.

Related Videos
Milind Desai, MD
Masanori Aikawa, MD
Neil Goldfarb, GPBCH
Mabel Mardones, MD.
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester
Screenshot of Susan Wescott, RPh, MBA
Screenshot of an interview with Adam Colborn, JD
Screenshot of an interview with James Chambers, PhD
Screenshot of an interview with Megan Ehret, PharmD
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.